BSDM ...Sehr interessantes Investment !!!! - 500 Beiträge pro Seite

[BrauchGeld]

Ich bin hier vorhin zu 1,80$ (4000st) eingestiegen , was ich bisher über die Firma gelesen hab hat mich überzeugt .

Unter anderem steht eine US-Zulassung für das BSD-2000 System bevor das schon fast Weltweit zugelassen ist .

Mit diesem Gerät wurden sehr gute Ergebnisse in verschiedenen Krebsarten erzielt aber lest am besten selbst .


Bald gibts mehr über BSDM ...


BSD Medical (BSDM)

Marktkap: 39,8 Mio$
Cash: 6 Mio$
Kurs: 1,81 $

Shares Out: 22 M


Modernste Anlage für Wärmebehandlung gegen Krebs eröffnet
http://www.uk-erlangen.de/e467/e583/e5789/e8158/index_ger.ht…


BSD Medical Corporation Reports Continuation of FDA Review of BSD-2000 Hyperthermia System
SALT LAKE CITY -- November 18, 2009
http://www.bsdmedical.com/press_view.php?press_id=317


BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia System in Combination with Chemotherapy
http://www.bsdmedical.com/press_view.php?press_id=322


BSD Medical Reports Publication of Chinese Study Using the BSD-2000 Hyperthermia System to Treat Lung Cancer
http://www.bsdmedical.com/press_view.php?press_id=326


News
http://www.bsdmedical.com/more-press.php

[BrauchGeld]

Noch hat das gepushe nicht angefangen

[BrauchGeld]

Hab nochmal 3000st zugelegt bevor es bald losgeht .

[sacha1978]

Antwort auf Beitrag Nr.: 39.071.742 von BrauchGeld am 05.03.10 18:01:58

Hallo Brauchgeld

Ich persöhnlich finde das momentanige Volumen relativ dünn.....
...bin mir aber auch am überlegen einzusteigen...das was ich gelesen habe hat ziehmlich überzeugt....

Greez

[BrauchGeld]

Das Unternehmen ist Top und die aussichten auf Kursgewinne ebenso...

Heat helps in cancer treatment

http://www.thestarphoenix.com/opinion/Heat+helps+cancer+trea…

[BrauchGeld]

Sennewald ist Präsident und CEO von Sennewald Medizintechnik GMBH und ist auch ein Direktor von BSDM .Sennewald ist grösster Aktionär von BSDM mit 6,5 Mio Aktien .

http://www.sennewald.de/deu/index.htm

http://biz.yahoo.com/t/74/6487.html

Weltweit erste randomisierte Phase III-Studie belegt Wirksamkeit der regionalen Hyperthermie in Kombination mit Chemotherapie bei Sarkomen
http://idw-online.de/pages/de/news213086


Mehr Infos ? Einfach hier anklicken und selber forschen
http://www.google.de/#hl=de&q=bsd-2000+hyperthermie&start=10…


Von Frost & Sullivan gabs auch schon eine Auszeichnung




Hyperthermie könnte schon sehr bald zur Standarttherapie gehören und BSDM wäre ganz ganz weit vorne dabei .

[BrauchGeld]

http://www.cancerdecisions.com/content/view/285/2/lang,engli…

A Victory for Hyperthermia in Bladder Cancer

There was another victory for the use of regional deep hyperthermia in the treatment of cancer. The latest victory occurred in the treatment of high-risk bladder cancer. Heat treatment, delivered via the BSD 2000 machine, improved such patients' five-year survival rate from 67 to 80 percent. The local tumor control rate went from 63 to 81 percent. In addition, the disease-specific survival was 88 percent, metastasis-free survival was 89 percent, and the bladder-preserving rate was 96 percent at three years.


The median number of weekly hyperthermia treatments that patients received was five (with a range of 1-7). So some of the patients received just a single hyperthermia treatment, yet their results were averaged with the rest. Not surprisingly, there was a correlation between the number of hyperthermia treatments patients received and their overall survival rate -simply put, those who received more frequent treatments did better (Wittlinger 2009).


The study was published in Radiotherapy and Oncology by Dr. Michael Wittlinger of the Department of Radiation Oncology at Erlangen University Medical School in Germany and seven colleagues. Radiotherapy and Oncology is the official publication of the European Society for Therapeutic Radiology and Oncology.


Other Studies Show the Same Effect


This is not the only study to demonstrate improved results when hyperthermia is added to conventional treatment for bladder cancer. Thus, Renzo Columbo, MD, of Milan, Italy, reported on a multi-center trial in which 83 patients with intermediate or high-risk bladder tumors who were randomized to receive either the drug mitomycin-C alone or the same drug plus hyperthermia (following bladder-sparing surgery). The recurrence rate for those receiving mitomycin C alone was 57.5 percent, but it plummeted to 17.1 percent in those who also received hyperthermia. That study appeared in the Journal of Clinical Oncology (Colombo 2003).


In addition, Jacoba van der Zee, MD, and colleagues at the Erasmus Medical Center in Holland reported on a prospective, randomized trial that included 101 bladder cancer patients. The addition of hyperthermia to radiotherapy significantly increased the complete tumor response rate (the disappearance of all local tumor) from 51 percent for those treated with radiotherapy alone to 73 percent in patients also treated with hyperthermia, a 22 percent improvement. The duration of local control was also significantly longer. That study was published in the Lancet (van der Zee 2000).


For the record, the same trial also included patients with cervical or rectal cancer patients. The treatment worked in all cancer types, but the response was even greater in cervical cancer, where hyperthermia increased the complete response (CR) rate from 57 to 83 percent, a 26 percent difference. The three-year survival rate went from 27 to 51 percent (Van der Zee 2000). As I reported in my newsletter of June 15, 2009, hyperthermia has now become part of standard treatment for cervical cancer in Holland and has been recommended as such by the German Cancer Society (Frankena 2008 and Frankena 2009). By contrast, the device used in the latest German trial, the BSD 2000, although made in the United States, is restricted to investigational use by the Food and Drug Administration (FDA).


The accumulating data on the benefits of hyperthermia gives the lie to the idea that American oncologists will adopt any therapeutic measure, provided that it is proven effective in clinical trials. In my opinion, a great many American patients will die needlessly before the cancer establishment wakes up to the fact that hyperthermia is a relatively harmless way of prolonging the lives of many cancer patients.

[BrauchGeld]

FAQ Video von BSDM
http://www.youtube.com/watch?v=p0zu74Wnm8w

[BrauchGeld]

BSDM ist wegen der KE etwas zurück gekommen die gelegenheit habe ich genutzt um weitere 3000st zukaufen .

2 US-Zulassungen stehen für dieses Jahr an und mit 35 Mio$ Marktkap ist die Aktie sehr billig .


BSD Medical Files FDA 510(k) Submission to Market Phase II MicroThermX Ablation System
http://finance.yahoo.com/news/BSD-Medical-Files-FDA-510k-bw-…



BSD Medical Corporation Reports Continuation of FDA Review of BSD-2000 Hyperthermia System
SALT LAKE CITY -- November 18, 2009
http://www.bsdmedical.com/press_view.php?press_id=317

[BrauchGeld]

Schönes Video ..BSD-2000 kommt in diesm film zum Einsatz http://www.zdf.de/ZDFmediathek/content/963222

http://www.sennewald.de/


Weitere Erfolge mit BSD-2000 in PIII...April 2010
http://finance.yahoo.com/news/BSD-Medical-Reports-Study-bw-5…

[greenhorn1998]

Kann das sein, dass BSD schon seit Jahren versucht für das BSD 2000-System das FDA-OK zu bekommen?

greenhorn

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.511.203 von greenhorn1998 am 12.05.10 21:38:10

Ja das übliche spiel halt mit der FDA aber es ging NIE um das Gerät selbst sondern nur ums papierkram .

Inzwischen ist alles geregelt und BSDM wartet nun auf die finale Entscheidung diesmal wird es gut gehen .

------------

Führender europäischer Anbieter von Hyperthermie-Systemen zur regionalen Tumorbehandlung
http://www.innovations-report.de/html/profile/profil-5654.ht…

[BrauchGeld]

Antwort auf Beitrag Nr.: 39.513.306 von BrauchGeld am 13.05.10 11:19:54

Hier handelt es sich um eine Qualitätsaktie ....


Regionale Hyperthermie verbessert Therapieergebnis für Patienten mit Weichteiltumoren 07.05.2010

http://www.innovations-report.de/html/berichte/medizin_gesun…


Ehrung für den Pionier der klinischen Hyperthermie
Dr. Sennewald erhält Timofeef-Ressovsky-Medaille in Rußland

http://www.innovations-report.de/html/berichte/preise_foerde…

[greenhorn1998]

Interessant ist das allemal, keine Frage.

Naja, mal schauen, jetzt muss erst mal Santhera liefern und die Aktie die gewünschte Reaktion nach oben zeigen Deutlichst, wenn es geht

greenhorn

[truberdixx]

wann ist denn hier mit News zurechnen?

[truberdixx]

Die Aktie kennt ja nur eine Richtung...

Ich schau mir das noch paar Tage an, dann bin ich auch raus. Haben das 52-Wochen-Tief schon unterschritten.

[WissenMacht]

es geht endlich los


BSD Medical Receives FDA 510(k) Clearance to Market the MicroThermX Microwave Ablation System
BSD Medical Receives FDA 510(k) Clearance to Market the MicroThermX Microwave Ablation System

Aug. 18, 2010 (Business Wire) -- BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market its MicroThermX Microwave Ablation System (MTX-180) for ablation of soft tissue. Clearance from the FDA of BSD’s 510(k) Premarket Notification submission authorizes the commercial sale of the MTX-180 in the United States. The MTX-180 was designed to provide a higher power, optimized system targeted to the growing therapeutic interventional and surgical oncology market.

The MTX-180 utilizes innovative synchronous phased array technology that was developed and patented by BSD to deliver targeted microwave energy to ablate (destroy) soft tissue. BSD employed its extensive 32-year background in developing thermal therapy systems in the design of the MTX-180. BSD’s patented and patents pending technology allows the MTX-180 to provide larger and more uniform zones of ablation during a single procedure. Third party independent testing was conducted at a U.S. university medical center that is a world leader in ablation treatments. The testing data demonstrated that the MTX-180 is a user-friendly system that delivers larger, more uniform ablation zones in shorter periods of time.

The MTX-180 is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MTX-180 is the first of its kind that allows delivery of higher power levels using a single generator. The delivery of microwave energy is controlled utilizing an interactive, touch screen monitor that allows the operator to quickly and easily control the treatment.

“The MTX-180 represents a significant advance in our strategy to diversify BSD’s products and increase revenue,” said Harold Wolcott, BSD President. “The MTX-180 introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2 billion. We believe that the MicroThermX System provides significant advantages over currently available devices that will allow us to capitalize on this rapidly expanding market.”

Currently, radiofrequency (RF) energy is utilized most frequently in the interventional oncology ablation market. Published studies have demonstrated that the use of microwave energy has numerous advantages over RF energy for the delivery of ablation therapy, including faster set-up, shorter ablation times, larger ablation zones, and higher intratumoral temperatures. For these reasons, interventional oncology key opinion leaders regard microwave as the future of soft tissue ablation therapy. The MTX-180 has been designed to provide optimized microwave ablation therapy.

The MTX-180 provides minimally invasive access to the target tissue and can be used in open surgical as well as in percutaneous ablation procedures, which will allow the MTX-180 to be used by both surgeons and interventional radiologists.

CE Marking approval for the MTX-180 System is imminent and will allow BSD to initiate a European market launch.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

[WissenMacht]

[WissenMacht]

wo hat die rally ein ende?

das potential von MTX 180 ist enorm wie kann man es beziffern?

marketcap müsste unter 80 mio liegen zu zeit